TABLE 2.
Antimicrobial resistance profile (including resistant and intermediate) of the IBD-associated E. coli isolates according to the type of the disease.
| Antibiotics | UC (n = 112) |
CD (n = 20) |
||
| Stool isolates (n = 77) |
Biopsy isolates (n = 35) |
Stool isolates (n = 8) |
Biopsy isolates (n = 12) |
|
| Piperacilline/Tazobactam | 21 (27.3) | 12 (34.3) | 2 (25) | 7 (58.3) |
| Cefazolin | 75 (97.4) | 34 (97.1) | 8 (100) | 11 (91.6) |
| Ciprofloxacin | 54 (70.1) | 27 (77.1) | 1 (12.5) | 9 (75) |
| Gentamicin | 10 (13) | 6 (17.1) | 1 (12.5) | 3 (25) |
| Cefoxitin | 35 (45.5) | 17 (48.6) | 2 (25) | 4 (33.3) |
| Cefepime | 44 (57.1) | 28 (80) | 3 (37.5) | 12 (100) |
| Cefotaxime | 51 (66.2) | 23 (65.7) | 4 (50) | 9 (75) |
| Tetracycline | 46 (59.7) | 23 (65.7) | 3 (37.5) | 6 (50) |
| Amikacin | 1 (1.3) | 6 (17.1) | 0 (0) | 0 (0) |
| Aztreonam | 36 (46.8) | 17 (48.6) | 1 (12.5) | 6 (50) |
| Ofloxacin | 42 (54.5) | 17 (48.6) | 1 (12.5) | 5 (41.7) |
| Ceftazidime | 43 (55.8) | 21 (60) | 3 (37.5) | 8 (66.6) |
| Imipenem | 4 (5.2) | 2 (5.7) | 0 (0) | 0 (0) |
| Ampicillin | 64 (83.1) | 30 (85.7) | 5 (62.5) | 11 (91.6) |
IBD, inflammatory bowel disease, UC, ulcerative colitis, CD, Crohn’s disease.